Unlock instant, AI-driven research and patent intelligence for your innovation.

Antibody of complete human-derived anticomplement factor H

A fully human, complement technology, applied in the direction of antibodies, anti-animal/human immunoglobulins, anti-tumor drugs, etc., can solve the problem of difficult to develop therapeutic reagents

Active Publication Date: 2017-09-01
ZHUHAI TRINOMAB BIOTECHNOLOGY CO LTD +1
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These natural regulator molecules of complement activation are typically larger than 100 kDa and difficult to develop into therapeutic agents

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody of complete human-derived anticomplement factor H
  • Antibody of complete human-derived anticomplement factor H
  • Antibody of complete human-derived anticomplement factor H

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1 Preparation of fully human monoclonal CFH antibody TRN1004

[0043] 1. PBMC Isolation and Single Memory B Cell Sorting

[0044] Using avidin-labeled CFH 15-mer polypeptide (SEQ ID NO: 9) as a bait, the flow cytometry sorter was used to sort out the pooled peripheral blood mononuclear cells (PBMC, collected from patients expressing CFH autoantibodies) Single memory B cells, CD20+ / CD27ALL / CFH- antigen-binding memory B cells were sorted by fluorescent-fluorescent labeling. To minimize false positives, Streptavidin Fluor647 and Brilliant Violet 421 were labeled with Alexa. Each fluorophore was labeled with streptavidin on a separate aliquot which was then mixed together and interacted with the biotinylated antigenic peptide. Cells of both fluorophores showing elevated fluorescence were sorted into wells of a single 96-well plate.

[0045] 2. Isolation of VHDJH and VL genes

[0046] VHDJH and VLJL gene segment pairs of mAb were amplified by RT / PCR from flow-sor...

Embodiment 2

[0057] Example 2 Binding site verification test

[0058] Biotin-labeled CFH 15-mer peptide antigen (SEQ ID NO:9), each amino acid was mutated separately to form 15 mutant peptides, plus the wild-type peptide as a positive control and the sequence-scrambled peptide as a As a negative control, use Elisa to detect the binding of the TRN1004 antibody to the above 18 polypeptides at different concentrations, draw a curve and calculate the Area Under Curve (AUC), and analyze the key binding sites between the antibody and the polypeptide. The result is as figure 2 It was shown that the key binding sites between the TRN1004 antibody and the CFH antigen polypeptide are the 5th, 6th, 7th, 8th, 11th, and 12th positions in the polypeptide sequence GPPPPIDNGDITSFP, which proves that it can specifically bind to the antigenic polypeptide. in, figure 2 Among them, CFH is positive control 1, its sequence is as shown in SEQ ID NO: 9, OR is positive control 2, its sequence is as shown in SEQ...

Embodiment 3

[0059] Example 3 Determination of antibody affinity

[0060] The capture molecules were coupled to the SA chip first, and then the dextran surface of the chip was activated, and the coupling amount was determined by the injection time. Finally, the SA chip was used to capture the molecular capture ligand: the prepared fully human anti-rabies virus neutralizing antibody was used as the ligand, and the signal value obtained by calculation was used to determine the injection concentration and contact time of the monoclonal antibody. Affinity and kinetics analysis of monoclonal antibody binding to CFH 15-mer polypeptide (antigen): CFH 15-mer polypeptide was diluted with HBS-EP buffer as analyte, analyte flowed through the chip in sequence with increasing concentration, and signals were obtained respectively curve. Each concentration was regarded as one cycle, and after completing one cycle, the chip was regenerated with 10 mmol / L glycine-hydrochloric acid to return to the origina...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
Login to View More

Abstract

The invention discloses an antibody of a complete human-derived anticomplement factor H. The invention discloses a monoclonal antibody with CFH (Complement Factor H) specificity. The monoclonal antibody disclosed by the invention is combined with a C-end structure domain of the CFH. The monoclonal antibody disclosed by the invention is capable of preventing a complement C3b from be depositing on the surfaces of cells, so that complement-derived cytotoxicity (CDC) can be inhibited. The invention further discloses the application of the monoclonal antibody in treating complement related diseases.

Description

technical field [0001] The invention discloses a fully human anti-complement factor H antibody and the application of the antibody in the preparation of medicines for treating complement-related diseases. Background technique [0002] The complement system is an important part of the human immune system. Complement not only participates in the physiological immune defense process, but also can cause immunopathological damage. Excessive activation of the complement system will directly or indirectly cause damage to its own organs and tissues. This in turn leads to an inflammatory response. More and more studies have found that persistent infection or chronic inflammatory stimulation may lead to the development of tumors. At present, studies have confirmed that the complement system is related to the occurrence of tumors (Markiewski MM, et al, 2008, 9(11):1225-1235). [0003] There are three pathways for the activation of the complement system: the classical pathway, the MBL...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/18C12N15/13C12N15/63A61K39/395G01N33/68A61P37/00A61P35/00
CPCA61K2039/505C07K16/18C07K2317/24C07K2317/31C07K2317/565C07K2317/622C07K2317/626G01N2333/4716
Inventor 廖化新袁晓辉王月明刘彤昝利鹏吴昌文张远旭
Owner ZHUHAI TRINOMAB BIOTECHNOLOGY CO LTD